Using lymphatic vessels to strategically target pancreatic ductal adenocarcinoma (LYMPDAC)

Utilizando los vasos linfáticos para atacar de forma estratégica el adenocarcinoma ductal pancreático (LYMPDAC)


Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide due to its rapid progression to an aggressive stage and the lack of effective therapies. PDAC aggressiveness is driven by intense fibroblast desmoplastic reaction that together with collapsed and leaky blood vessels leads to fluid accumulation generating a high interstitial fluid pressure (IFP). The elevated IFP is correlated with higher PDAC metastasis outcome. Strategies targeting cancer associated fibroblasts in PDAC have been so far contraproductive. Lymphatic vessels (LVs) that in PDAC are sparse and dysfunctional are crucial to drain the fluid from the tumor insterstitium.

Objetivos y Resultados

Here, the aim is to make a crossroad of mechanobiology and cellular biology to target PDAC. By inducing PDAC intratumoural formation of LVs a lower IFP will be achieved. This new mechanoenvironment will favour the delivery of chemo and angio/immunotherapies. This objective will be achieved by using a new and innovative technique, the use of microfluidic devices together with a robust in vivo mouse model of PDAC.

This study will be vital for advancing the fundamental understanding of the complex PDAC tumor microenvironment and will open new avenues to make effective therapies for PDAC patients. Importantly, the combination of biomechanics and cancer cell biology will entail new horizons for cancer therapeutics. Moreover, given the existence of organ-specific vascular organization, the modulation of LVs in a solid tumor different to subcutaneous melanoma or breast cancer models is a challenge nowadays and will uncover clinically relevant outputs.

IP IIS Aragón

Dra. Alejandra González Loyola

Supervisores: Dra. Patrícia Sancho Andrés, Dr. José Manuel García Aznar.

Organismo Financiador

Financiado por el Instituto de Salud Carlos III con cargo a los fondos europeos del Plan de Recuperación, Transformación y Resiliencia, con código de expediente IHMC22/00004 (“Using lymphatic vessels to strategically target pancreatic ductal adenocarcinoma”), en virtud de Resolución de la Dirección del Instituto de Salud Carlos III, O.A., M.P. de 22 de diciembre de 2022, por la que se conceden subvenciones “Sello de Excelencia ISCIII-HEALTH”, y “Financiado por la Unión Europea – NextGenerationEU”.


Alejandra González Loyola


No aplicable


20/06/2023 – 19/06/2025 (24 meses)

Página web

No disponible